Sat, Nov 29, 2014, 3:09 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

GW Pharmaceuticals plc Message Board

  • mrequity1 mrequity1 Oct 10, 2013 3:38 PM Flag


    Let's say the FDA approves Sativex for cancer pain and MS spasticity. What are the potential revenues? 400,000 MS patients, 100,000 with spasms uncontrolled. $750 million after partner gets their cut ($10,000 yearly cost). Cancer pain is tough to calculate. 400,000 with pain not controlled by opiates, but Sativex can reduce the amount of opiates needed for ALL cancer patients. A wild guess is maybe 1 million patients get Sativex. $6.5 Billion. Let's say $7 billion total and then cut that in half just because. So $3.5 Billion divided by 177 million ordinary shares. So $19 per share multiplied by 12 shares per ADR equals $228 revenue per ADR. Let's cut it in half again because I see through rose colored glasses. $114 in revenue per ADR. Biogen trades at 10 times revenue. Amgen at 5 times. What am I doing wrong?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
77.43-2.77(-3.45%)Nov 28 1:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exxon Mobil Corporation
NYSEFri, Nov 28, 2014 1:00 PM EST
Chevron Corporation
NYSEFri, Nov 28, 2014 1:00 PM EST